NBS NEWZZZ $12M CASH FROM ERYE CLOSURE // NeoStem Closes

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2012 at 10:26 AM

[b]NBS > NEWZZZ $12M CASH FROM ERYE CLOSURE [/b]// NeoStem Closes Divestiture of Its Ownership Interest in Suzhou Erye

2012-11-13 09:08 ET - News Release

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE:NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced that the Company has completed the divestiture of its 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company. The divestiture provides NeoStem with $12,280,000 in cash and removes from the Company's balance sheet over $30 million in short and long-term debt obligations. Erye also returns 1,040,000 shares representing approximately 0.7% of the Company's outstanding common stock, 1,170,000 stock options representing approximately 5.1% of the Company's outstanding options and 640,000 warrants to purchase common stock held by Erye representing approximately 1.1% of the Company's outstanding warrants.

"We are very pleased to have reached this significant milestone in our business," said Dr. Robin Smith, Chairman and CEO of NeoStem. "The Erye divestiture brings non-dilutive capital that bolsters our cash position in the United States, reduces legal and financial reporting expenditures, simplifies our financial statements and focuses our efforts exclusively on the rapidly growing cell therapy industry. The divestiture also paves the way for the Company to qualify for new funding through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program which would support our pre-clinical development of VSELTM Technology. NeoStem will also be able to invest more resources into its cell therapy development and contract manufacturing activities."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: For more information, please contact:
Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gilat's Revenue Dip Spurs Legal Scrutiny for Investors

Gilat Satellite's Surprise Revenue Shortfall If anybody thought the satellite business was all about science fiction-esque technology, here's a reality check: when earnings don't meet expectations, shareholders get jittery. This seems to be exactly what's happening with Gilat Satellite Networks Ltd. (NASDAQ: GILT). After twice reaffirming their fiscal 2026 revenue...

FIS Under Investigation: Legal Woes Hit Shareholders

When Forecasts Falter: A Reality Check for FIS Investors You ever get the feeling a company is just a bit too optimistic? Well, Fidelity National Information Services, Inc. (NYSE: FIS) might've been playing that game up until its recent fiscal hiccup. The mess started on November 4, 2026, when FIS decided to slash its fiscal 2026 adjusted EPS outlook. From a Wall Street...

Rizzi Steps Down; Mogler Takes Helm at ALTOUR

Changes in Leadership: The ALTOUR Shakeup You know, in the travel world, shifts in leadership can be quite the rollercoaster ride. We're talking about some pretty big shoes to fill over at ALTOUR, with Gabe Rizzi stepping back after a decade of driving the company's dynamic evolution. He’s not entirely out of the picture, though. Rizzi’s going to hang around as a...

Peanuts and Diabetes: A Surprising Health Link

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Coastal Financial Faces Crisis as Lawsuit Deadline Looms

Coastal Financial Caught in a Storm Folks are buzzing about the drama unraveling around Coastal Financial (NASDAQ:CCB), and it's not for good reasons. Shares nose-dived a jaw-dropping 43.52%, leaving investors feeling like they got hit by a freight train. The culprit? A messy soup of financial woes and alleged misinformation. A Deep Dive into the Numbers Let's rip the...

Webull Faces Class Action Over China Ties Missteps

What's Brewing with Webull? Troubling allegations have bubbled to the surface regarding Webull Corporation, now in the crosshairs of a securities class action. The heart of this legal storm is the claim that Webull, under the ticker NASDAQ:BULL, allegedly disguised its deep-seated ties with China. And boy, when those revelations hit the news on October 7, 2026, it sent...

Data Center Cooling: Air vs. Liquid Battle Heats Up

Cooling Market: A Hot Green Showdown Here's the scene: data centers, churning out digits like a Wall Street broker spits out numbers, are in the middle of a seismic shift. We're talking about the cooling sector jumping from $19.5 billion in 2026 to a mind-boggling $42 billion by 2031. Now that's more of a leap than a hop, if you ask me. But the rocket fuel behind this...

HanAll F&B Maps Bold U.S. Entry with Strategic Pivot

Diving into Uncharted Waters HanAll F&B is setting its sights on the U.S. market, a move that could be make-or-break for this South Korean food manufacturer. With their recent rebranding from Taebaek Sanchae Naengmyeon Farming Association, they're not just changing names—they're shifting operational gears. The name might sound new, but the gutsy ambition behind it is as...

Understanding Cataracts: What Investors Should Know

The Subtle Slowdown in Vision When it comes to cataracts, things don't just suddenly hit you like a ton of bricks. It’s a slow burn—cataracts develop over months or even years. Your vision starts feeling like it’s giving up on high definition. The lens in your eye starts to get cloudy, like a fog rolling in on a morning drive. You're not going to wake up one day...

Spain's Young Entrepreneurs Get a Boost from Temu

Paving New Paths for Spanish Startups Temu and CEAJE are shaking hands to jumpstart a new era for Spanish entrepreneurs, promising to flip the script on digital growth and international outreach. This partnership is a big deal, aiming to leverage both parties' strengths to provide young business owners across Spain with the tools they need to ride the digital wave. A...